Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic MelanomaAmod A. Sarnaik, Jason Chesney, Omid Hamid et al.|Journal of Clinical Oncology|2021Cited by 431
Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).Adi Diab, Brendan D. Curti, Mario Q. Marcondes et al.|Journal of Clinical Oncology|2019Cited by 26
Proinflammatory phenotype with imbalance of KLF2 and RelA: Risk of childhood stroke with sickle cell anemiaJudy Enenstein, Robert P. Hebbel, Liming Milbauer et al.|American Journal of Hematology|2009Cited by 18
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumorsAdi Diab, Sandra P. D’Angelo, Brendan D. Curti et al.|Regular and Young Investigator Award Abstracts|2020Cited by 15
Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors.Yusra F. Shao, Justin C. Moser, Geoffrey T. Gibney et al.|Journal of Clinical Oncology|2022Cited by 1